239 related articles for article (PubMed ID: 17786308)
1. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells.
Liang Y; Besch-Williford C; Benakanakere I; Hyder SM
Int J Oncol; 2007 Oct; 31(4):777-84. PubMed ID: 17786308
[TBL] [Abstract][Full Text] [Related]
2. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein.
Liang Y; Besch-Williford C; Hyder SM
Int J Oncol; 2009 Nov; 35(5):1015-23. PubMed ID: 19787255
[TBL] [Abstract][Full Text] [Related]
3. Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics.
Liang Y; Besch-Williford C; Brekken RA; Hyder SM
Cancer Res; 2007 Oct; 67(20):9929-36. PubMed ID: 17942925
[TBL] [Abstract][Full Text] [Related]
4. p53-dependent inhibition of progestin-induced VEGF expression in human breast cancer cells.
Liang Y; Wu J; Stancel GM; Hyder SM
J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):173-82. PubMed ID: 15860260
[TBL] [Abstract][Full Text] [Related]
5. Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.
Liang Y; Besch-Williford C; Benakanakere I; Thorpe PE; Hyder SM
Breast Cancer Res Treat; 2011 Jan; 125(2):407-20. PubMed ID: 20349129
[TBL] [Abstract][Full Text] [Related]
6. Regression of progestin-accelerated 7,12-dimethylbenz[a]anthracene-induced mammary tumors in Sprague-Dawley rats by p53 reactivation and induction of massive apoptosis: a pilot study.
Benakanakere I; Besch-Williford C; Ellersieck MR; Hyder SM
Endocr Relat Cancer; 2009 Mar; 16(1):85-98. PubMed ID: 19075036
[TBL] [Abstract][Full Text] [Related]
7. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status.
Supiot S; Zhao H; Wiman K; Hill RP; Bristow RG
Radiother Oncol; 2008 Mar; 86(3):407-11. PubMed ID: 18237796
[TBL] [Abstract][Full Text] [Related]
8. WTp53 induction does not override MTp53 chemoresistance and radioresistance due to gain-of-function in lung cancer cells.
Cuddihy AR; Jalali F; Coackley C; Bristow RG
Mol Cancer Ther; 2008 Apr; 7(4):980-92. PubMed ID: 18413811
[TBL] [Abstract][Full Text] [Related]
9. In vitro and in vivo cytotoxic effects of PRIMA-1 on hepatocellular carcinoma cells expressing mutant p53ser249.
Shi H; Lambert JM; Hautefeuille A; Bykov VJ; Wiman KG; Hainaut P; Caron de Fromentel C
Carcinogenesis; 2008 Jul; 29(7):1428-34. PubMed ID: 18048389
[TBL] [Abstract][Full Text] [Related]
10. PRIMA-1 cytotoxicity correlates with nucleolar localization and degradation of mutant p53 in breast cancer cells.
Russo D; Ottaggio L; Penna I; Foggetti G; Fronza G; Inga A; Menichini P
Biochem Biophys Res Commun; 2010 Nov; 402(2):345-50. PubMed ID: 20946886
[TBL] [Abstract][Full Text] [Related]
11. PRIMA-1, a mutant p53 reactivator, restores the sensitivity of TP53 mutant-type thyroid cancer cells to the histone methylation inhibitor 3-Deazaneplanocin A.
Cui B; Yang Q; Guan H; Shi B; Hou P; Ji M
J Clin Endocrinol Metab; 2014 Jun; 99(6):E962-70. PubMed ID: 24512488
[TBL] [Abstract][Full Text] [Related]
12. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax.
Wang T; Lee K; Rehman A; Daoud SS
Biochem Biophys Res Commun; 2007 Jan; 352(1):203-12. PubMed ID: 17113036
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of proliferation of T47D human breast cancer cells: alterations in progesterone receptor and p53 tumor suppressor protein.
Dinda S; Kodali-Gali S; Sevilla L; Burkley M; Hurd C; Moudgil VK
Mol Cell Biochem; 1997 Oct; 175(1-2):81-9. PubMed ID: 9350037
[TBL] [Abstract][Full Text] [Related]
14. PRIMA-1 selectively induces global DNA demethylation in p53 mutant-type thyroid cancer cells.
Qiang W; Jin T; Yang Q; Liu W; Liu S; Ji M; He N; Chen C; Shi B; Hou P
J Biomed Nanotechnol; 2014 Jul; 10(7):1249-58. PubMed ID: 24804545
[TBL] [Abstract][Full Text] [Related]
15. Novel ovarian cancer maintenance therapy targeted at mortalin and mutant p53.
Ramraj SK; Elayapillai SP; Pelikan RC; Zhao YD; Isingizwe ZR; Kennedy AL; Lightfoot SA; Benbrook DM
Int J Cancer; 2020 Aug; 147(4):1086-1097. PubMed ID: 31845320
[TBL] [Abstract][Full Text] [Related]
16. Short preoperative treatment with erlotinib inhibits tumor cell proliferation in hormone receptor-positive breast cancers.
Guix M; Granja Nde M; Meszoely I; Adkins TB; Wieman BM; Frierson KE; Sanchez V; Sanders ME; Grau AM; Mayer IA; Pestano G; Shyr Y; Muthuswamy S; Calvo B; Krontiras H; Krop IE; Kelley MC; Arteaga CL
J Clin Oncol; 2008 Feb; 26(6):897-906. PubMed ID: 18180460
[TBL] [Abstract][Full Text] [Related]
17. PRIMA-1 induces p53-mediated apoptosis by upregulating Noxa in esophageal squamous cell carcinoma with TP53 missense mutation.
Furukawa H; Makino T; Yamasaki M; Tanaka K; Miyazaki Y; Takahashi T; Kurokawa Y; Nakajima K; Takiguchi S; Mori M; Doki Y
Cancer Sci; 2018 Feb; 109(2):412-421. PubMed ID: 29168598
[TBL] [Abstract][Full Text] [Related]
18. Mutant p53: a novel target for the treatment of patients with triple-negative breast cancer?
Synnott NC; Murray A; McGowan PM; Kiely M; Kiely PA; O'Donovan N; O'Connor DP; Gallagher WM; Crown J; Duffy MJ
Int J Cancer; 2017 Jan; 140(1):234-246. PubMed ID: 27615392
[TBL] [Abstract][Full Text] [Related]
19. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells.
Rehman A; Chahal MS; Tang X; Bruce JE; Pommier Y; Daoud SS
Breast Cancer Res; 2005; 7(5):R765-74. PubMed ID: 16168122
[TBL] [Abstract][Full Text] [Related]
20. Human chorionic gonadotropin suppresses human breast cancer cell growth directly via p53-mediated mitochondrial apoptotic pathway and indirectly via ovarian steroid secretion.
Yuri T; Kinoshita Y; Emoto Y; Yoshizawa K; Tsubura A
Anticancer Res; 2014 Mar; 34(3):1347-54. PubMed ID: 24596382
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
